The suppliers of a new drug to treat anemia in patients undergoing kidney dialysis have recalled the product after reports that it had caused severe allergic reactions, including some that were fatal, the Wall Street Journal and New York Times report. Affymax and Takeda Pharmaceutical’s Omontys competes with Amgen Inc.’s Epogen-Aranesp franchise.